{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:14:15Z","timestamp":1769634855872,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.lungcan.2020.06.033","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T14:43:37Z","timestamp":1593528217000},"page":"21-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study"],"prefix":"10.1016","volume":"147","author":[{"given":"Soo-Young","family":"Yoon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Joon","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Kyung","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Hoon","family":"Maeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2020.06.033_bib0005","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0342-x","article-title":"Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"19","key":"10.1016\/j.lungcan.2020.06.033_bib0010","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2020.06.033_bib0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.lungcan.2020.06.033_bib0020","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study","volume":"35","author":"Bauml","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2020.06.033_bib0025","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.lungcan.2020.06.033_bib0030","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Keynote, Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.06.033_bib0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2020.06.033_bib0040","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.lungcan.2020.06.033_bib0045","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2020.06.033_bib0050","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2020.06.033_bib0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2020.06.033_bib0060","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol."},{"issue":"10027","key":"10.1016\/j.lungcan.2020.06.033_bib0065","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lungcan.2020.06.033_bib0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-018-0332-z","article-title":"Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab","volume":"6","author":"Acero Brand","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2020.06.033_bib0075","first-page":"807","article-title":"Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab","volume":"17","author":"Lederhandler","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.lungcan.2020.06.033_bib0080","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.14309\/crj.2017.57","article-title":"Severe Esophagitis and Gastritis from Nivolumab Therapy","volume":"4","author":"Boike","year":"2017","journal-title":"ACG Case Rep. J."},{"issue":"2","key":"10.1016\/j.lungcan.2020.06.033_bib0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12094-019-02273-x","article-title":"SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)","volume":"22","author":"Majem","year":"2020","journal-title":"Clin. Transl. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.06.033_bib0090","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4103\/0973-1482.146090","article-title":"Radiation recall phenomenon presenting as myositis triggered by carboplatin plus paclitaxel and related literature review","volume":"10","author":"Maeng","year":"2014","journal-title":"J. Cancer Res. Ther."},{"issue":"2","key":"10.1016\/j.lungcan.2020.06.033_bib0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/CCO.0000000000000352","article-title":"Radiotherapy in combination with immune checkpoint inhibitors","volume":"29","author":"De Ruysscher","year":"2017","journal-title":"Curr. Opin. Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2020.06.033_bib0100","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.06.033_bib0105","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trialassessing theefficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2020.06.033_bib0110","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000278","article-title":"Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management","volume":"3","author":"Geukes Foppen","year":"2018","journal-title":"ESMO Open"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:39:16Z","timestamp":1759235956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220305079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":22,"alternative-id":["S0169500220305079"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.06.033","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}